Rosas-Nava JE, Manzanilla-García HA, Pérez-Ávila RJ, Almanza-González MS, Virgen-Gutiérrez JF

Language: Spanish
References: 7
Page: 243-246
PDF size: 2188.29 Kb.

ABSTRACT

Management of post-chemotherapy residual mass is surgical. However, due to complications that may present, it has become controversial. Chemotherapy is the initial treatment for stage II and stage III seminoma. The case of a patient with giant post-chemotherapy residual retroperitoneal mass that was managed surgically with no complications and adequate postoperative progress is presented.

REFERENCES

1. Stephenson AJ, Tal R, Sheinfeld J. Adjunctive nephrectomy at postchemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol 2006;176(5):1996-9.

2. Mosharafa AA, Foster RS, Leibovich BC, Bihrle R, Johnson C. Is postchemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 2003;169(6):2126-8.

3. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM. Recurrence pattern and proposed surveillance protocol following post-chemotheraphy retroperitoneal lymph node dissection. J Urol 2007;177(1):131-8.

4. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 2006;176(4 Pt 1):1463-7.

5. Vergouwe Y, Steyerberg EW, Foster RS, Habbema JD, Donohue JP. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. Urol 2001;165(1):84-8.

6. Ogan K, Lotan Y, Koeneman K, Pearle MS, Cadeddu JA. Laparoscopic versus open retroperitoneal lymph node dissection: a cost analysis. J Urol 2002;168(5):1945-9.

7. Walsh P, et al. Campbell: Urología. 8a ed. Tomo 4. Buenos Aires: Médica Panamericana, 2004; 3216.